p-iodophenol-enhanced luminol chemiluminescent assay applied to discrimination between acute lymphoblastic and minimally differentiated acute myeloid (FAB-M0) or acute megakaryoblastic (FAB-M7) leukemias

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorda Costa, M.
dc.creatorXimenes, Valdecir Farias
dc.creatorBrunetti, Iguatemy Lourenço
dc.creatorFalcao, R. P.
dc.creatorFonseca, Luiz Marcos da
dc.date2014-05-20T13:24:25Z
dc.date2016-10-25T16:45:08Z
dc.date2014-05-20T13:24:25Z
dc.date2016-10-25T16:45:08Z
dc.date2004-01-01
dc.date.accessioned2017-04-05T20:00:03Z
dc.date.available2017-04-05T20:00:03Z
dc.identifierHematology Journal. London: Nature Publishing Group, v. 5, n. 6, p. 496-499, 2004.
dc.identifier1466-4860
dc.identifierhttp://hdl.handle.net/11449/7563
dc.identifierhttp://acervodigital.unesp.br/handle/11449/7563
dc.identifier10.1038/sj.thj.6200562
dc.identifierWOS:000227379500007
dc.identifierhttp://dx.doi.org/10.1038/sj.thj.6200562
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/856173
dc.descriptionIntroduction: In this report, we propose the application of the p-iodophenol-enhanced luminol chemiluminescent technique to the determination of peroxidase (myeloperoxidase and/or platelet peroxidase) activity in blasts of minimally differentiated acute myeloblastic leukemia (AML-M0) and acute megakaryoblastic leukemia (AML-M7).Methods: the frozen blast cells from 29 patients were thawed and submitted to the optimized protocol.Results: All cases of AML-M7 and AML-M0 exhibited integrated light emission greater than 73 (10(2) mV x s), which was the arbitrary cutoff point set for the discrimination between AML and acute lymphoblastic leukemia (ALL) (mean + 3 x s.d. of ALL samples, n = 10). In addition, five out of seven cases of AML-M0 showed results above the Cutoff point.Conclusion: This highly sensitive enhanced chemiluminescent technique may be applied to discriminate between ALL and AML-M7 or AML-M1 cases, and most AML-M0 cases. It is very simple, cheap and easy to perform compared to other procedures used to measure MPO activity in AML-leukemias including AML-M7 and AML-M0.
dc.languageeng
dc.publisherNature Publishing Group
dc.relationHematology Journal
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectacute myeloid leukemia (AML)
dc.subjectacute lymphoblastic leukemia (ALL)
dc.subjectchemiluminescence
dc.subjectluminol
dc.subjectp-iodophenol
dc.subjectmyeloperoxidase (MPO)
dc.subjectplatelet peroxidase (PPO)
dc.titlep-iodophenol-enhanced luminol chemiluminescent assay applied to discrimination between acute lymphoblastic and minimally differentiated acute myeloid (FAB-M0) or acute megakaryoblastic (FAB-M7) leukemias
dc.typeOtro


Este ítem pertenece a la siguiente institución